StockData
Filana Therapeutics, Inc. logo

Filana Therapeutics, Inc. (FLNA) shareholders

FLNANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$0.64+0.08 (+14.52%)

Close on Nov 20, 2026Market cap $30.98MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
26.2%
13M of 48M shares
Institutional holders
85
8 new, 22 sold out
Net institutional buying
-1M
In Q2 2026
Insider trades, 12 months
10 buys · 0 sales
Net bought $749.50K

Shares held by institutions

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of FLNAValueChange% of portfolio
Vanguard Capital Management LLC1,974,9814.09%$2.35M+44,0380.00%
Two Sigma Investments, LP1,711,3583.54%$2.04M−277,4560.00%
Marshall Wace, Llp1,597,5483.31%$1.90M−414,9950.00%
BlackRock, Inc.1,453,5613.01%$1.73M+39,0470.00%
Goldman Sachs Group Inc668,7921.38%$795.86K+627,4680.00%
Geode Capital Management, LLC615,5101.27%$732.74K+19,2680.00%
D. E. Shaw & Co., Inc.485,0251.00%$577.18K−74,1800.00%
Gmt Capital Corp450,1000.93%$535.62K–0.03%
Renaissance Technologies LLC389,6010.81%$463.63K+62,8420.00%
Squarepoint Ops LLC318,3800.66%$378.87KNew0.00%
Vanguard Fiduciary Trust Co315,8890.65%$375.91K+41,9580.00%
Acadian Asset Management LLC295,0590.61%$350.00K+10,8460.00%
Susquehanna International Group, Llp292,0170.60%$347.50K−155,2610.00%
Gsa Capital Partners Llp269,4100.56%$321.00K+51,5660.02%
Group One Trading, L.P.244,0080.51%$290.37K−58,6160.00%
State Street Corp209,1050.43%$248.84K−30,8820.00%
Vanguard Portfolio Management LLC132,5970.27%$157.79K−960.00%
Connor, Clark & Lunn Investment Management Ltd.132,2980.27%$157.44K−4,6330.00%
Federated Hermes, Inc.119,9520.25%$142.74K+4,8550.00%
Northern Trust Corp114,3220.24%$136.04K−34,8720.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 20268513M26.2%8 / 2133 / 221M2M
Q1 202610114M28.3%15 / 1738 / 205M3M
Q4 202510714M28.6%22 / 2529 / 153M3M
Q3 202510314M29.7%20 / 2132 / 134M2M
Q2 20259712M25.5%18 / 2333 / 382M6M
Q1 202511716M32.8%18 / 2941 / 362M4M
Q4 202413717M36.0%31 / 4535 / 546M3M
Q3 202416114M29.1%37 / 5035 / 185M2M
Q2 202414513M27.7%23 / 6023 / 172M1M
Q1 202414212M25.0%15 / 4643 / 250M3M
Q4 202315315M30.1%31 / 4539 / 163M2M
Q3 202314013M26.8%16 / 5432 / 252M1M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

27 funds held FLNA in Q2 2026, 75% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of FLNAValue% of fundAs of
Vanguard Total Stock Market Index Fund1,365,8432.83%$1.63M0.00%Jun 30, 2026
Vanguard Extended Market Index Fund563,8831.17%$671.02K0.00%Jun 30, 2026
Fidelity Extended Market Index Fund283,0130.59%$435.84K0.00%May 31, 2026
iShares Micro-Cap ETF148,5900.31%$176.82K0.01%Jun 30, 2026
Vanguard Health Care Index Fund132,1170.27%$203.46K0.00%May 31, 2026
Fidelity Total Market Index Fund81,4610.17%$125.45K0.00%May 31, 2026
Fidelity Series Total Market Index Fund72,4740.15%$111.61K0.00%May 31, 2026
Goldman Sachs Absolute Return Tracker Fund42,6050.09%$50.70K0.00%Jun 30, 2026
Fidelity Nasdaq Composite Index Fund39,9530.08%$61.53K0.00%May 31, 2026
Invesco NASDAQ Future Gen 200 ETF33,7010.07%$51.90K0.27%May 31, 2026
Fidelity ZERO Total Market Index Fund31,0560.06%$31.37K0.00%Jul 31, 2026
Vanguard Balanced Index Fund24,5250.05%$29.18K0.00%Jun 30, 2026
Vanguard Institutional Total Stock Market Index Fund20,7300.04%$24.67K0.00%Jun 30, 2026
Fidelity ZERO Extended Market Index Fund16,0780.03%$16.24K0.00%Jul 31, 2026
Blackstone Alternative Multi-Strategy Fund10,6000.02%$12.61K0.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Richard BarryPresident & CEO, Director1,955,9474.05%Nov 20, 2026
Eric SchoenChief Financial Officer31,5000.07%Nov 18, 2026
Robert Christopher CookChief Operating& Legal Officer135,3000.28%Nov 18, 2026
Freda NassifChief Business Officer––Apr 21, 2025
James William KupiecChief Medical Officer0–Dec 3, 2024
Robert Eugene Anderson JrDirector27,6000.06%Nov 20, 2026
Jill M. QuigleyDirector––Nov 12, 2026
Dawn Carter BirDirector––Oct 22, 2025
Patrick J. Md Scannon PhdDirector1,0000.00%Jul 16, 2025
Pierre GravierDirector––May 27, 2025
Robert Z. GussinDirector10,6170.02%May 27, 2025
Claude NicaiseDirector––May 27, 2025
Donnell Michael J. ODirector65,8120.14%May 27, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Robert Eugene Anderson Jr
Director
Nov 18, 2026Buy+19,000$0.52$9.88K27,600
Richard Barry
President & CEO, Director
Nov 18, 2026Buy+44,851$0.52$23.32K1,955,947
Richard Barry
President & CEO, Director
Nov 17, 2026Buy+132,926$0.48$63.80K1,911,096
Richard Barry
President & CEO, Director
Nov 16, 2026Buy+440,206$0.47$206.90K1,778,170
Eric Schoen
Chief Financial Officer
Nov 16, 2026Buy+20,000$0.42$8.40K31,500
Robert Christopher Cook
Chief Operating& Legal Officer
Nov 16, 2026Buy+121,575$0.46$55.92K135,300
Richard Barry
President & CEO, Director
Sep 30, 2026Buy+100,000$0.92$92.00K1,337,964
Richard Barry
President & CEO, Director
Sep 29, 2026Buy+206,813$0.90$186.13K1,237,964
Richard Barry
President & CEO, Director
Sep 28, 2026Buy+93,091$0.84$78.20K1,031,151
Robert Eugene Anderson Jr
Director
Nov 24, 2025Buy+8,600$2.90$24.94K8,600
Richard Barry
President & CEO, Director
Nov 20, 2025Buy+150,000$2.76$414.00K938,060
Richard Barry
President & CEO, Director
Nov 19, 2025Buy+73,385$2.75$201.81K788,060
Robert Christopher Cook
Chief Operating & Legal Office
Sep 30, 2025Buy+13,725$2.91$39.94K13,725
Richard Barry
President & CEO, Director
Sep 22, 2025Buy+7,172$2.28$16.35K714,675
Richard Barry
President & CEO, Director
Sep 19, 2025Buy+46,908$2.29$107.42K707,503
Richard Barry
President & CEO, Director
Sep 19, 2025Buy+400$2.25$900660,595
Richard Barry
President & CEO, Director
Sep 18, 2025Buy+185,233$2.24$414.92K660,195
Richard Barry
President & CEO, Director
Sep 18, 2025Buy+5,400$2.13$11.50K474,962
Eric Schoen
Chief Financial Officer
Nov 29, 2024Sale−59,800$3.86$230.83K11,500
Eric Schoen
Chief Financial Officer
Nov 29, 2024Sale−2,000$3.82$7.64K0
Eric Schoen
Chief Financial Officer
Nov 29, 2024Option exercise+50,000$1.18$59.00K71,300
James William Kupiec
Chief Medical Officer
Nov 29, 2024Sale−4,000$3.87$15.48K0
Sanford Robertson
Director
May 16, 2024Gift−5,000––950,851
Sanford Robertson
Director
May 16, 2024Gift+5,000––5,000
Sanford Robertson
Director
Apr 26, 2024Option exercise+69,000$22.00$1.52M955,851
Richard Barry
Director
Apr 23, 2024Option exercise+176,085$22.00$3.87M469,562
James William Kupiec
Chief Medical Officer
Apr 18, 2024Option exercise+1,500$22.00$33.00K4,000
Eric Schoen
Chief Financial Officer
Apr 17, 2024Option exercise+1,500$22.00$33.00K21,300
Sanford Robertson
Director
Aug 23, 2023Buy+30,000$17.45$523.50K886,851
Richard Barry
Director
Aug 22, 2023Buy+16,571$16.65$275.91K293,477
Richard Barry
Director
Aug 21, 2023Buy+1,906$16.80$32.02K276,906
Patrick J. Md Scannon Phd
Director
Jun 12, 2023Option exercise+1,000$0.95$9501,000
Remi Barbier
President and CEO, Director
May 24, 2023Option exercise+14,285$16.87$240.99K390,397
Remi Barbier
President and CEO, Director
May 24, 2023Tax withholding−47,723$25.25$1.21M734,279
Remi Barbier
President and CEO, Director
May 24, 2023Option exercise+71,428$16.87$1.20M782,002
Remi Barbier
President and CEO, Director
May 24, 2023Tax withholding−9,545$25.25$241.01K380,852
Sanford Robertson
Director
May 10, 2023Option exercise+2,142$16.66$35.69K856,851
Sanford Robertson
Director
May 10, 2023Option exercise+3,571$19.60$69.99K851,138
Sanford Robertson
Director
May 10, 2023Option exercise+3,571$16.66$59.49K854,709
Robert Z. Gussin
Director
May 1, 2023Tax withholding+7,077$23.34$165.18K10,617
Robert Z. Gussin
Director
May 1, 2023Option exercise+2,142$16.66$35.69K10,552
Robert Z. Gussin
Director
May 1, 2023Option exercise+3,571$16.66$59.49K14,123
Robert Z. Gussin
Director
May 1, 2023Option exercise+3,571$19.60$69.99K17,694
Donnell Michael J. O
Director
Mar 7, 2023Tax withholding−2,778$25.20$70.01K6,873
Donnell Michael J. O
Director
Mar 7, 2023Tax withholding−2,361$25.20$59.50K9,651
Donnell Michael J. O
Director
Mar 7, 2023Option exercise+3,571$19.60$69.99K12,012
Donnell Michael J. O
Director
Mar 7, 2023Option exercise+3,571$16.66$59.49K8,441
Richard Barry
Director
Mar 7, 2023Buy+77,276$25.76$1.99M275,000
Richard Barry
Director
Mar 6, 2023Buy+11,565$26.13$302.19K197,724
Nadav Friedmann
Chief Medical Officer, Director
Oct 3, 2022Option exercise+9,376$0.95$8.91K79,910
Sanford Robertson
Director
Sep 8, 2022Option exercise+2,802$23.59$66.10K1,027,567
Richard Barry
Director
Aug 23, 2022Buy+36,159$23.79$860.22K186,159
James William Kupiec
Chief Clinical Dev. Officer
Aug 23, 2022Buy+2,500$24.44$61.10K2,500
Eric Schoen
Chief Financial Officer
Aug 12, 2022Buy+2,500$19.95$49.88K19,800
Sanford Robertson
Director
Aug 12, 2022Buy+100,000$20.69$2.07M1,024,765
Remi Barbier
President and CEO, Director
Jun 7, 2022Other−57,143––710,574
Remi Barbier
President and CEO, Director
Jun 6, 2022Tax withholding−54,720$27.93$1.53M767,717
Remi Barbier
President and CEO, Director
Jun 6, 2022Option exercise+65,368$23.38$1.53M822,437
Nadav Friedmann
Chief Medical Officer, Director
May 27, 2022Tax withholding−21,498$26.66$573.14K70,534
Nadav Friedmann
Chief Medical Officer, Director
May 27, 2022Option exercise+3,501$23.38$81.85K70,590

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
12.31%
6M shares short
Days to cover
20.6
At 0M shares a day
Change since last report
+1.4%
From 6M shares
Short volume, 20 days
41.5%
Of volume reported to FINRA

Shares sold short, last 9 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Filana Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 50,134 shares on Aug 31, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Eric Schoen
Officer
Dec 2, 20242,000$7.64KNov 29, 2024RETAIL PURCHASE
Eric Schoen
Officer
Nov 29, 202459,800$230.97KNov 29, 2024STOCK OPTION EXERCISE

Congress trades

5 trades in Filana Therapeutics reported by 1 member of the House

MemberTypeTradedAmountFiled
Christopher L. Jacobs
NY27
BoughtDec 12, 2022$1K–15KJan 20, 2023
Christopher L. Jacobs
NY27
SoldNov 8, 2022$1K–15KDec 12, 2022
Christopher L. Jacobs
NY27
BoughtOct 12, 2022$1K–15KNov 16, 2022
Christopher L. Jacobs
NY27
SoldJul 18, 2022$1K–15KSep 9, 2022
53 days late
Christopher L. Jacobs
NY27
BoughtJun 21, 2022$15K–50KJul 28, 2022

See a number that looks wrong?